Licenses its gene-delivery platform to biotechnology and pharmaceutical companies and develops one-time gene therapies for patients with retinal, neuromuscular and neurodegenerative diseases.
10-K for FY2025, filed Mar 5, 2026Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our…View ↗
We have developed a broad pipeline of investigational AAV therapeutics using our NAV Technology Platform as one-time treatments to address…View ↗
For many years, by sublicensing NAV Vectors from our NAV Technology Platform to other biopharmaceutical companies with disease-specific…View ↗
We are currently focusing our internal development pipeline in three areas: retinal diseases, neuromuscular diseases and neurodegenerative…View ↗
Biotechnology and pharmaceutical partners pay for NAV platform rights; the company earns license fees when it delivers the rights, royalties when licensed products sell, and service fees as it performs development or manufacturing work.
10-K for FY2025, filed Mar 5, 2026The Company licenses its NAV Technology Platform and other intellectual property rights to other biotechnology and pharmaceutical…View ↗
The transaction price of the Company's license and collaboration arrangements is allocated to the underlying performance obligations based…View ↗
Royalties on sales of licensed products, sales-based milestone payments, including milestones payable upon first commercial sales of…View ↗
Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$170.4M
10-K for FY2025, filed Mar 5, 2026
$170.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License and royalty
Licensed
10-K for FY2025, filed Mar 5, 2026 |
92%
FY2022: 100%
|
License and royalty, FY2025
$156.3M Sources
|
Licensed |
|
Service
Recurring
|
8.3% |
Service, FY2025
$14.2M Sources
|
Recurring |
Biotechnology and pharmaceutical companies contract directly with REGENXBIO under license and collaboration agreements; named partners include Novartis Gene Therapies and Nippon Shinyaku.
10-K for FY2025, filed Mar 5, 2026
No. It lost $193.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$40.7MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 24, 2026
ROCKVILLE, Md., August 24, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121…View ↗
Shrinking. Revenue fell 64% in 4 years, from $470.3M in FY2021 to $170.4M in FY2025, about 22% a year.
Partnered gene therapies
The older report names Zolgensma as a partnered program; the latest report also names Itvisma, expanding the platform's partnered product lineup.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 5, 2026For many years, by sublicensing NAV Vectors from our NAV Technology Platform to other biopharmaceutical companies with disease-specific…View ↗
For many years, by sublicensing NAV Vectors from our NAV Technology Platform to other biopharmaceutical companies with disease-specific…View ↗
Competes with 4D Molecular Therapeutics, Amicus Therapeutics, Astellas Pharma, BioMarin Pharmaceutical, Lilly, MeiraGTx, Novartis, Passage Bio, PTC Therapeutics, Roche, Sanofi, Sarepta Therapeutics, Solid Biosciences, Taysha Gene Therapies, Tenaya Therapeutics, Ultragenyx Pharmaceutical, uniQure, Regeneron Pharmaceuticals, Amgen, and Kodiak Sciences
10-K for FY2025, filed Mar 5, 2026We are aware of a number of companies focused on developing and commercializing gene therapies in various disease indications, including 4D…View ↗
Loading...